Beacon Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 2/6
Beacon Pharmaceuticals has a total shareholder equity of BDT6.1B and total debt of BDT10.1B, which brings its debt-to-equity ratio to 165.4%. Its total assets and total liabilities are BDT17.7B and BDT11.6B respectively. Beacon Pharmaceuticals's EBIT is BDT1.3B making its interest coverage ratio 1.3. It has cash and short-term investments of BDT300.5M.
Key information
165.4%
Debt to equity ratio
৳10.12b
Debt
| Interest coverage ratio | 1.3x |
| Cash | ৳300.46m |
| Equity | ৳6.12b |
| Total liabilities | ৳11.57b |
| Total assets | ৳17.69b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: BEACONPHAR's short term assets (BDT11.9B) exceed its short term liabilities (BDT8.8B).
Long Term Liabilities: BEACONPHAR's short term assets (BDT11.9B) exceed its long term liabilities (BDT2.8B).
Debt to Equity History and Analysis
Debt Level: BEACONPHAR's net debt to equity ratio (160.5%) is considered high.
Reducing Debt: BEACONPHAR's debt to equity ratio has increased from 60.2% to 165.4% over the past 5 years.
Debt Coverage: BEACONPHAR's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: BEACONPHAR's interest payments on its debt are not well covered by EBIT (1.3x coverage).